KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Beginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashDeferred TaxesDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Change in Working Capital: 2009-2017

Historic Change in Working Capital for Teva Pharmaceutical Industries (TEVA) over the last 9 years, with Dec 2017 value amounting to -$890.0 million.

  • Teva Pharmaceutical Industries' Change in Working Capital fell 847.90% to -$890.0 million in Q4 2017 from the same period last year, while for Dec 2017 it was -$1.6 billion, marking a year-over-year decrease of 234.95%. This contributed to the annual value of -$435.0 million for FY2024, which is 504.17% down from last year.
  • Latest data reveals that Teva Pharmaceutical Industries reported Change in Working Capital of -$890.0 million as of Q4 2017, which was down 1,922.73% from -$44.0 million recorded in Q3 2017.
  • In the past 5 years, Teva Pharmaceutical Industries' Change in Working Capital ranged from a high of $1.1 billion in Q2 2013 and a low of -$890.0 million during Q4 2017.
  • Its 3-year average for Change in Working Capital is $41.2 million, with a median of $37.5 million in 2016.
  • Per our database at Business Quant, Teva Pharmaceutical Industries' Change in Working Capital soared by 784.27% in 2015 and then slumped by 847.90% in 2017.
  • Over the past 5 years, Teva Pharmaceutical Industries' Change in Working Capital (Quarterly) stood at $359.0 million in 2013, then soared by 41.23% to $507.0 million in 2014, then tumbled by 57.20% to $217.0 million in 2015, then plummeted by 45.16% to $119.0 million in 2016, then plummeted by 847.90% to -$890.0 million in 2017.
  • Its Change in Working Capital was -$890.0 million in Q4 2017, compared to -$44.0 million in Q3 2017 and -$248.0 million in Q2 2017.